Intratumoral Bromelain + Acetylcysteine in Relapsed and Unresectable Pseudomyxoma Peritonei
Status:
Recruiting
Trial end date:
2023-09-01
Target enrollment:
Participant gender:
Summary
This trial pursues studying a compassionate treatment option for patients with inoperable
pseudomyxoma peritonei through percutaneous administration of bromelain + N-acetylcysteine
(NAC) in order to decrease tumoral volume. Secondary endpoints are the decrease of ascites,
compressive symptoms and pain through the dilution of mucins, which would better intestinal
blockage.
Phase:
Phase 1
Details
Lead Sponsor:
Maimónides Biomedical Research Institute of Córdoba